drugset / Trial / NCT02223013
Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
Comparative pharmacokinetics and tolerability of two experimental extended release formulations and a standard formulation of BIBV 308 SE following multiple doses.
Timeline
- Start
- 1999-04
- Primary completion
- 1999-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Terbogrel | Small molecule | 50 mg | Oral |
Indications
No indication recorded.